March 22, 2007
Dr. Nieca Goldberg, Associate Professor of Medicine and Medical Director, NYU Women’s Heart Program, and Co-Medical Director, 92nd Street Y’s Cardiac Rehabilitation Center, 3-22-07
Dr. Nieca Goldberg is a cardiologist and a nationally recognized pioneer in women’s heart health. Her New York City practice Total Heart Care focuses primarily on caring for women. Dr. Goldberg is Associate Professor of Medicine and Medical Director of NYU Women’s Heart Program, the Co-Medical Director of the 92nd Street Y’s Cardiac Rehabilitation Center, a national spokesperson for the American Heart Association’s “Go Red” campaign, an AHA volunteer for over 15 years and served as a board member in NYC. Previously she was the Chief of Women’s Cardiac Care at Lenox Hill Hospital.
Dr. Goldberg is the author of the award winning and highly acclaimed book Women Are Not Small Men, which is now updated and entitled The Women’s Healthy Heart Program – Lifesaving Strategies for Preventing and Healing Heart Disease, published by Ballantine Books.
Dr. Goldberg’s research and medical publications are concerned with cardiovascular disease in women, exercise imaging and exercise. She has appeared many times on The Today Show as well as The View, Good Morning America, The Early Show, and CBS Evening News. In addition she has been featured and interviewed by reporters from The Wall Street Journal, The New York Times, Fitness Magazine, and many others discussing women and heart disease. She serves on the Woman’s Day Editorial Advisory Board.
Matt Clouse, Director, U.S. Environmental Protection Agency’s Green Power Partnership, 3-22-07
Matt Clouse is Director of the U.S. Environmental Protection Agency’s Green Power Partnership. This voluntary, climate protection program seeks to reduce greenhouse gas emissions by building demand for renewable power. EPA’s growing numbers of Green Power Partners are purchasing more than seven billion kilowatt-hours of renewable power annually. This electricity would be equivalent to roughly ten billion pounds of CO2 if generated by conventional means.
Matt joined the EPA in late 2000 to begin developing the Green Power Partnership, which was launched in July 2001. Almost six years later, the Partnership has over 650 partners including 310 organizations or facilities buying green power for 100% of their electricity usage, 83 government agencies, 70 colleges & universities, and 39 Fortune 500 companies.
The broader voluntary market has grown with EPA’s focus on building demand for green power among corporate, governmental and institutional electricity consumers. Now non-residential sales drive market growth and the market supports over 3000 MW of new renewable power capacity.
Matt’s career in environmental and energy policy began in Oregon at an environmental lab and includes five years at the Oregon Department of Environmental Quality and two years at the University of Delaware where he received a Masters of Energy And Environmental Policy and led teams tasked with developing Delaware’s climate change action plan and the state’s energy plan.
March 15, 2007
Dr. Herbert A. Hauptman, Nobel Laureate and President, Hauptman-Woodward Medical Research Institute, 3-15-07
After more than 20 years with the Naval Research Laboratory in Washington, D.C., Herbert A. Hauptman, Ph.D, joined the staff of the Hauptman-Woodward Medical Research Institute in 1970 (then known as the Medical Foundation of Buffalo). In 1985, he was awarded the Nobel Prize in Chemistry. Although he is a mathematician by training who has taken only one chemistry course in his life, he was able to use classical mathematics to resolve an issue that had stymied chemists for decades.
The structures of thousands of molecules have now been solved by crystallographers using Dr. Hauptman's direct methods, and many new molecular structures are added to the list each year. As a result of the information obtained in these studies, many new drugs have been designed. In honor of Dr. Hauptman’s work, as well as to honor the original donor who made the Institute a reality, the Medical Foundation of Buffalo was renamed the Hauptman-Woodward Medical Research Institute in 1994.
Dr. Hauptman's current work builds on his earlier Nobel-winning research. He and his colleagues at the Hauptman-Woodward Institute are presently working to extend the methods of structure determination to very large molecules of biological importance, including the proteins that are the targets for drug-design efforts. They have achieved new success in recent years by developing a procedure known as "Shake-and Bake" that has greatly extended the power of direct methods
The Hauptman-Woodward Medical Research Institute (HWI) is an independent, not-for-profit, biomedical research facility located in the heart of downtown Buffalo's medical campus. For half a century, HWI scientists have been committed to improving human health through study, at a molecular level, of the causes and potential cures of many diseases. In contrast to clinical research, the focus of Hauptman-Woodward’s basic research is to determine the structures of individual substances such as proteins that play a role in the development of specific diseases. This research explores questions like the following: What is the three-dimensional shape of a particular protein molecule? How and with what does this protein interact? What controls these interactions? What structural alterations lead to the development of disease?
Working under the leadership of Nobel Laureate Herbert Hauptman, HWI scientists use the techniques of molecular biology, biochemistry, and crystallography to answer these questions. The results of their investigations provide the starting point for better drug design. In addition, other research on-going at HWI seeks to improve the methods of crystallization and data analysis used for molecular structure determination by scientists worldwide.
Dr. Buddy Ratner, Chairman, Scientific Advisory Board, Ratner BioMedical Group, and Professor of Bioengineering and Professor of Chemical Engineering, University of Washington, 3-15-07
Dr. Buddy D. Ratner is the Michael L. and Myrna Darland Endowed Chair in Technology Commercialization, Professor of Bioengineering and Professor of Chemical Engineering at the University of Washington. He received his Ph.D. (1972) in polymer chemistry from the Polytechnic Institute of Brooklyn. Professor Ratner is a past president of the Society for Biomaterials, a fellow of the American Institute of Medical and Biological Engineering (AIMBE), a fellow of AVS The Science and Technology Society and a Fellow, Biomaterials Science and Engineering (FBSE).
Dr. Ratner served as president of AIMBE, 2002-2003. He was vice president of the Tissue Engineering Society International (TESI) 2003-2005. In 2002 he was elected a member of the National Academy of Engineering, USA.
Dr. Ratner is the author of more 400 scholarly works. His research interests include biomaterials, tissue engineering, polymers, biocompatibility, surface analysis of organic materials, self-assembly, nanobiotechnology and RF-plasma thin film deposition. He has won the Clemson Award for Contributions to the Biomaterials Literature, the C.M.A. Stine Award in Materials Science (AIChE), the Medard W. Welch Award (AVS) and the 2005-6 C. William Hall Award of the Society For Biomaterials. Dr. Ratner was most recently elected a Fellow of the American Association For the Advancement of Science (AAAS).
Ratner BioMedical Group (RBG) LLC seeks to develop and build on its portfolio of exclusively optioned and in-licensed technologies in novel biomaterials and pharmacologic agents. This will be done to advance medical care in tissue regeneration, wound healing, and unique biomaterials for enhanced drug delivery, among other applications. The Company’s broad collection of intellectual property will fuel the creation of a number of portfolio companies spanning diverse disciplines and therapies. RBG technologies stem from the intersections of materials science, engineering, modern biology and medicine, and have synergistic potential for translation to unique biomedical products and services. The company optioned exclusive license rights to 24 patents, patent applications and university technology disclosures with the intent of commercializing all these technologies.
David Stanley Ely, 2006-07 National Siemens Advanced Placement Teacher of the Year, 3-15-07
David Stanley Ely was recently named the 2006-07 National Siemens Advanced Placement Teacher of the Year for his dedication to the AP Program both inside and outside the classroom. A biology teacher at Champlain Valley Union High School in Hinesberg, VT for nearly 35 years, this is the latest of many honors he has received, including the Vermont Teacher of the Year, an Advanced Placement Teacher Recognition Award and the Vermont Academy of Science and Engineering Teaching Excellence Award.
Mr. Ely’s enthusiasm extends far beyond the classroom and he has participated in and coordinated 65 local, state, and national summer institutes and workshops. In addition to his teaching responsibilities, he is a lifetime member of the National Association of Biology Teachers (NABT), the National Science Teachers Association (NSTA), Vermont Science Teachers Association, and the Association of Presidential Awardees for Excellence in Science Teaching. He serves as a board member for the Green Mountain Audubon Society, UVM’s Institutional Care and Use Committee, the Vermont Standards Board Professional Educators, and the Vermont Academy of Arts and Sciences.
March 12, 2007
Dr. Philip Campbell, Editor-in-Chief, Nature, 3-29-04
Dr. Philip Campbell has been the Editor-in-Chief of Nature since December 1995. He is a director of the Nature Publishing Group, having overall responsibility for the editorial quality of all Nature publications. Dr. Campbell is a Fellow of the Royal Astronomical Society and a Fellow of the Institute of Physics. Under his editorship, Nature has won several prestigious publishing awards from the Periodical Publishers’ Association, including International Magazine of the Year in 1998. Nature’s circulation has grown significantly since 1996, and has the highest impact factor of multidisciplinary journals.
March 08, 2007
Dr. Antonio Giordano, Director, Sbarro Institute for Cancer Research and Molecular Medicine, and President and Chairman of the Board, Sbarro Health Research Organization, 3-8-07
Antonio Giordano, M.D., Ph.D., Director, Sbarro Institute for Cancer Research and Molecular Medicine; Director, Center of Biotechnology, Temple University's College of Science and Technology; and President and Chairman of the Board, Sbarro Health Research Organization. Dr. Giordano has been an internationally recognized researcher specializing in the genetics of cancer and gene therapy for 20 years.
At 26, while a post-doctoral fellow at Cold Spring Harbor Laboratory in New York, Dr. Giordano discovered the protein p60, later named cyclin A, a substance that regulates growth in the cell cycle. At Temple University, he discovered Rb2/p130, a tumor suppressor gene which has since been found to be active in lung, endometrial, brain, breast, liver and ovarian cancers, and CDK9 and CDK10, guardians of the human genome. Research has subsequently shown that CDK9 plays a critical role in cell differentiation, particularly in muscles; HIV transcription; and the inception of tumors.
But Dr. Giordano has not limited his activities to the lab. Recognizing that scientists often make their most exciting discoveries while they are young, in 1993, while at Thomas Jefferson University, he founded the Sbarro Institute for Cancer Research and Molecular Medicine with the generous help of Mario Sbarro, president of Sbarro, Inc., an internationally successful restaurant chain.
In 2002, the Institute forged an exciting alliance with Temple University, forming the Sbarro Health Research Organization (SHRO). Under the agreement, funds from SHRO go directly to the Sbarro Institute for Cancer Research and Molecular Medicine at Temple, where promising researchers from around the globe pursue groundbreaking research in the molecular workings of cancer and other devastating diseases. The agreement with Temple was renewed in 2005, with the addition of two new research programs in molecular therapeutics and the study of the connections between obesity and cancer.
Since 1992, Dr. Giordano has been awarded nine patents, with six pending. He has published 270 papers on his work in the fields of cell cycles, gene therapy and the genetics of cancer and serves on the editorial of a number of professional journals. His work is funded by National Institutes of Health (NIH) grants, as well as individual and program project grants from SHRO. He has received a number of international awards for his work in cancer research.
The Sbarro Health Research Organization (SHRO) funds innovative and dedicated clinicians, molecular biologists, geneticists and chemists who seek to diagnose and cure cancer and cardiovascular conditions by identifying and studying the underlying molecular mechanisms of these diseases. The Organization also funds work on the links between obesity and cancer along with a new molecular therapeutics program that will spur the application of the newest discoveries to useful drug or diagnostic therapies for a wide range of diseases.
SHRO is pledged to support the study and development of new scientific strategies to diagnose and cure all forms of cancer and cardiovascular disease. In carrying out this mission, the organization is dedicated not only to attracting excellent scientists to work in the field of molecular genetics, but to training and expanding the numbers of future researchers through its outreach programs for undergraduates and high school students worldwide.
As SHRO allocates funding for pure research, the organization also recognizes the importance of applied research. Ultimately, the goal is to produce therapeutic and diagnostic treatments that will aid doctors and patients in their fight against disease. At present, most of the funds collected by SHRO are distributed to the Sbarro Institute for Cancer Research and Molecular Medicine located at the College of Science and Technology of Temple University in Philadelphia, Pennsylvania.
The Sbarro Institute for Cancer Research and Molecular Medicine was founded in 1993 by Antonio Giordano, MD, Ph.D. with the generous contributions of Mario Sbarro, owner of Sbarro, Inc., an internationally successful fast food chain. Initially, it was affiliated with Thomas Jefferson University in Philadelphia, Pennsylvania.
In 2002, scientists supported by the Institute forged a three-year alliance with Temple University. Specific research at the Institute revolves around investigations of the cell cycle and growth control, as well as the changes that cause a normal cell to turn cancerous. Much of the work focuses on how disease causing genes alter the normal functions of healthy cells.
Scientists at the Sbarro Institute for Cancer Research and Molecular Medicine have completed research on new technologies designed to diagnose lung, ovarian, endometrial, breast and brain tumors as well as lymphomas. Their work with gene therapy has also led to new strategies to treat tumors of the lung and brain.
Under a new agreement with the University in 2005, the Institute received continued funding from Temple, while expanding its program to include work on the relationship between obesity and cancer and a new program on molecular therapeutics, which will explore how molecular genetic research can be applied to patient therapies and diagnostics.
Dr. Nathan Cady, Assistant Professor of Nanobioscience, The College of Nanoscale Science and Engineering, University of Albany, Albany, NY, 3-8-07
One of Dr. Nathan Cady's key areas of research is developing methods to study biological processes at the nano- and microscale. This involves development of microfluidic biosensors and novel detection technologies. He is currently extending his previous work with nucleic-acid based biosensors by researching the development of sensors that are capable of detecting multiple organisms and/or DNA sequences within single samples. This type of multiplex analysis is relevant for clinical diagnostic purposes, genetic analysis, and detection of biowarfare agents. To develop these multiplex systems, Dr. Cady is exploring new optical and electrical detection strategies, including the use of quantum dots and organic thin-film transistors (OTFTs).
Beyond his research in biosensor technology, Dr. Cady is focusing on broader nanobiotechnology research. He is particularly interested in how cells interact with their environment at the nanoscale, especially how they adhere to, move along, and penetrate different surfaces. One of the more difficult conditions to control when studying cell-surface interactions is the large variability of the surfaces and environments that are used.
By better understanding how cells interact with these defined, nanoscale environments, Dr. Cady plans to provide insight for bioengineering applications such as materials biocompatibility, prosthetics and medical device design. This research effort will also address fundamental properties of how microorganisms, especially pathogenic bacteria, interact with surfaces to cause disease. To date there have been relatively few research groups using nanotechnology to answer these questions, making this an exciting and challenging field for new exploration.
Dr. Cady reeived his Ph.D. in Microbiology and B.A. in Biology from Cornel University (2005 and 1999, respectively).
The University of Albany College of Nanoscale Science and Engineering is the first college in the world dedicated to research, development, education, and deployment in the emerging disciplines of nanoscience, nanoengineering, nanobioscience, and nanoeconomics. In May 2006, it was ranked as the nation’s number one college for nanotechnology and microtechnology in the Annual College Ranking by Small Times magazine. CNSE’s Albany NanoTech complex is the most advanced research facility of its kind at any university in the world - a $3.5 billion, 450,000-square-foot complex that attracts corporate partners from around the world and offers students a one-of-a-kind academic experience.
The UAlbany NanoCollege houses the only fully integrated, 300mm wafer, computer chip pilot prototyping and demonstration line within 65,000 square feet of Class 1 capable cleanrooms. Over 1600 scientists, researchers, engineers, students, and faculty work on site at CNSE’s Albany NanoTech complex, including IBM, AMD, SONY, Toshiba, Qimonda, Honeywell, ASML, Applied Materials, Tokyo Electron, and Freescale. An expansion currently underway will increase the size of CNSE’s Albany NanoTech complex to over 750,000 square feet, including over 80,000 square feet of Class 1 cleanroom space, to house over 2000 scientists, researchers, engineers, students, and faculty by the end of 2008.
Bruce Jacobsen, Founder and CEO, and Mark Bretl, Vice President, Kinetic Books Company, 3-8-07
Bruce Jacobsen was previously general manager of Microsoft’s Kids/Games Business Unit and President of RealNetworks, Inc.
While working at Microsoft, Bruce developed educational products and games, and directed a renaissance of the Microsoft games group as it moved its products to Windows and invested in the game category. He led the business unit that developed the initial Magic School Bus software titles and developed a word processor and art package for students.
In 2000, Bruce left RealNetworks to teach physics to high school students and he wondered why education was taking so long to embrace technology. He saw how Encarta and the Internet had transformed how students access information and learn, and wondered why textbooks were still in print. Seven years later, Kinetic Books digital textbooks are in use by thousands of high schools and colleges in over 40 states and 15 countries.
Bruce received his B.A. summa cum laude from Yale University, and was elected to Phi Beta Kappa. He received his M.B.A. from Stanford University with little distinction but much relief.
Mark Bretl is a seasoned professional with over two decades of experience in the software industry prior to coming to Kinetic Books. He previously served as president of Tecmar, Inc., followed by a position as COO of Vivo Software Inc., which was acquired by RealNetworks, Inc. Mark served as Vice President at RealNetworks, and joined Kinetic Books in January 2004.
Mark earned his B.S. in Physics at the University of Wisconsin. While earning his degree, he worked in the Mission Control Main Engines Group at NASA Johnson Space Center during the first Space Shuttle launch, and at Monsanto Research Corporation doing particle collisions in a low pressure chamber.
Kinetic Books Company creates and publishes Kinetic Textbooks, the next generation of digital curriculum. The company’s full line of textbooks have been adopted in every state that has gone through a physics text approval process since Kinetic Books introduced its products in 2005, and two of its textbooks have been approved by The College Board for Advanced Placement coursework.
March 01, 2007
Dr. Edwin C. Krupp, Astronomer and Director of Griffith Observatory, 3-1-07
Dr. Edwin C. Krupp is an astronomer and Director of Griffith Observatory, a position he has held since his appointment in 1974. He first joined the Griffith Observatory in 1970, working as a part-time Planetarium Lecturer, and upon completion of his graduate degree, was appointed Curator in 1972. He is now recognized internationally as an expert on ancient, prehistoric, and traditional astronomy, and has visited nearly 1800 ancient and prehistoric sites throughout the world, regularly leading field study tours to exotic locations that have astronomical and archaeological interest.
Dr. Krupp is the author and editor of several books on the celestial component of human belief systems, including In Search of Ancient Astronomies, Archaeoastronomy and the Roots of Science, and Echoes of the Ancient Skies. His fourth book for adults, Beyond the Blue Horizon – Myths and Legends of the Sun, Moon, Stars, and Planets, is a worldwide comparative study of celestial mythology. His most recent book for adults, Skywatchers, Shamans, & Kings: Astronomy and the Archaeology of Power, was published in 1997. He also writes astronomy books for children illustrated by Robin Rector Krupp, including The Comet and You, The Big Dipper and You, The Moon and You, and The Rainbow and You. Dr. Krupp has received four national prizes for his writing. He is a contributing editor for Sky & Telescope and writes a monthly column that emphasizes the cultural component of astronomy for this nationally distributed magazine.
Dr. Krupp has received numerous national awards for his work, including the 1989 Klumpke-Roberts Award from the Astronomical Society of the Pacific for outstanding contributions to public understanding and appreciation of astronomy, the 1996 G. Bruce Blair Medal from the Western Amateur Astronomers for substantive contributions to amateur and public astronomy, and the 2002 Clifford W. Holmes Award.
Opened in 1935, Griffith Observatory is one of the best-known and most visited public observatories in the world. Operated by the City of Los Angeles’s Department of Recreation and Parks, the Observatory welcomed nearly 70 million visitors into the building prior to closing for renovation in January 2002. Construction on the renovation and expansion project began in October 2002. Griffith Observatory officially reopened to the public Friday, November 3, 2006, after finishing a $93-million facelift to renovate and expand the historic landmark.
Griffith Observatory’s unique architecture and setting, compelling programmatic offerings, and cinematic exposure have made it one of the most famous and visited landmarks in southern California. Tens of millions have come to walk the inside of the building, view the live planetarium shows, or simply gaze out toward the coast and the heavens. This cultural and scientific icon owes its existence to the dream of one man, Griffith Jenkins Griffith, and to the dedicated scientists and public servants who worked to fulfill his vision of making astronomy and observation accessible to all.
Dr. Barbara Hempstead, O. Wayne Isom Professor of Medicine and Co-Division Chief, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University and New York-Presbyterian Hospital, 3-1-07
Read the transcript of the SCIENCE AND SOCIETY interview with Dr. Barbara Hempstead
Download Adobe Reader here
Dr. Barbara L. Hempstead is a member of the Association of American Physicians and the American Society for Clinical Investigation. Among the honors and awards she has received are the Clinical Investigator Award from the National Cancer Institute and the Clinical Scientist Award in Translational Science from the Burroughs Wellcome Fund.
Dr. Hempstead has authored more than 70 scientific articles, with two papers published in Science and one in Nature in the last four years. Five of her articles are rated “Must Read” or higher in the Faculty of 1000 rankings. She has been Editor of the Journal of Investigational Medicine, and is a member of the editorial board of Journal of Biological Chemistry. She was Vice Chair for the Gordon Conference “Neurotrophic Factors” in 2003, and Chair in 2005.
The primary focus of Dr. Hempstead’s basic research is the role of growth factors called neurotrophins, and their receptors in human physiology and pathology. While some of her work has revealed how neurotrophins function in the arena in which most people study them, i.e., the brain and nervous system, her lab has conducted pioneering research in the roles that neurotrophins play outside the nervous system - in the cardiovascular system and on stem and progenitor cells that form blood. A major focus has been in identifying the actions of neurotrophins in promoting blood vessel growth, with implications in wound healing, atherosclerotic disease and tumor biology.
Weill Cornell Medical College—located in New York City—is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine. The Medical College, which is a principal academic affiliate of New York-Presbyterian Hospital, offers an innovative curriculum that integrates the teaching of basic and clinical sciences, problem-based learning, office-based preceptorships, and primary care and doctoring courses. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research in such areas as stem cells, genetics and gene therapy, geriatrics, neuroscience, structural biology, cardiovascular medicine, AIDS, obesity, cancer and psychiatry—and continue to delve ever deeper into the molecular basis of disease in an effort to unlock the mysteries behind the human body and the malfunctions that result in serious medical disorders.
Weill Cornell Medical College is the birthplace of many medical advances—from the development of the Pap test for cervical cancer to the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., and most recently, the world’s first clinical trial for gene therapy for Parkinson’s disease. Weill Cornell’s Physician Organization includes 650 clinical faculty, who provide the highest quality of care to their patients.
Richard Garozzo, Senior Composites Engineer in the Polymer Nanocomposites and Composites Group, University of Dayton Research Institute, and Manager, UDRI’s Center for Multifunctional Polymer Nanocomposites and Devices, 3-1-07
Richard Garozzo is a Senior Composites Engineer in the Polymer Nanocomposites and Composites Group at the University of Dayton Research Institute (UDRI), as well as Manager of UDRI’s Center for Multifunctional Polymer Nanocomposites and Devices (CMPND). He has more than 20 years experience performing research and development in advanced composite materials, including process development and characterization of advanced composite materials and carbon-carbon systems, as well as tooling development.
Mr. Garozzo has extensive experience in numerous forms of composite and plastic processing and in composite reinforcements and matrix systems. He is also well versed in plastics and rubber molding materials, and in developing parts for man-rated programs for the aerospace, medical and automotive industries. Earlier in his career, Mr. Garozzo was President and CEO of P&R Wheel and Water Sports, a multimillion dollar dealership for sales and service of composite vessels. He received his master of science degree in nonmetallic material science from California State University in 1978.
The University of Dayton Research Institute’s Center for Multifunctional Polymer Nanocomposites and Devices (CMPND) is the world’s first manufacturing center for product demonstration of nano-enhanced polymer composites. Created in collaboration with the National Composite Center in Dayton, OH, where it is located, the facility gives manufacturers the opportunity to evaluate state-of-the-art materials in their composite products, but without the major investment dollars and risk involved in purchasing new equipment and retooling their facilities.
The CMPND facility features a 10-foot autoclave, a 440-ton injection molding machine, a laser profiler and other equipment, in addition to lab and office space, and services include materials testing, prototype development and small production runs.
Manufacturers have access to the facility and its technologies, as well as UDRI staff expertise in nanomaterials. UDRI can also help manufacturers reduce the transition time of new materials to the marketplace.
UDRI’s CMPND is part of a larger program for the development of polymer nanomaterials and devices funded by Ohio’s Third Frontier Project. Other partners in the umbrella program are Ohio State University, working in the area of biosensors, and the University of Akron, working in polymer photonics.